CNBCLean R·
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Read at CNBC →
Business · 1 sources covering this
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/00b7ba4fdcf7e399269eb7d5507c9cb648e2dfdf" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s"></iframe>
